公开(公告)号：US20230071098A1

公开(公告)日：2023-03-09

申请号：US17259816

申请日：2019-07-16

Applicant: Noile-Immune Biotech, Inc.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Keishi ADACHI

IPC: C07K16/30 ,  C07K14/54 ,  C07K14/52 ,  A61P35/00 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  A61P1/16

Abstract: The present invention aims to provide a CAR that contains a single-chain antibody capable of specifically binding to GPC3 localized in the cell membrane and is useful for cancer immunotherapy using a CAR-T cell; and an immunocompetent cell expressing such a CAR. A gene encoding a CAR containing: a single-chain antibody that contains specific heavy-chain CDR1 to CDR3 and specific light-chain CDR1 to CDR3, as defined in claim 1, and specifically binds to a human-derived GPC3 polypeptide; a transmembrane region fused to a carboxyl terminus of the single-chain antibody; and an immunocompetent cell activation signaling transduction region fused to a carboxyl terminus of the transmembrane region is produced, and the gene is introduced into an immunocompetent cell. Thereby, a CAR-expressing immunocompetent cell having excellent cytotoxic activity on cancer cells and interferon gamma (IFN-γ) producibility can be produced.

公开(公告)号：US20240191192A1

公开(公告)日：2024-06-13

申请号：US18554372

申请日：2022-04-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  NOILE-IMMUNE BIOTECH INC.

Inventor： Soichiro OGAKI ,  Hideo ARAKI ,  Eiki MAEDA

IPC: C12N5/0783 ,  C07K16/28

CPC classification number: C12N5/0636 ,  C07K16/2809 ,  C07K16/2818 ,  C12N2510/00

Abstract: Provided is a method for activating T cells comprising the step of activating T cells in a medium containing a CD3 agonist and/or a CD28 agonist for more than 36 hours and less than 48 hours; a method for producing genetically modified T cells, comprising the steps of activating T cells according to the activation method, introducing an exogenous gene into the activated T cells, and culturing the T cells into which the exogenous gene has been introduced; a cell population comprising genetically modified T cells obtained by the production method; and a matrix of mobile polymer chains or a bead supporting a CD3 agonist and/or a CD28 agonist, wherein the matrix or bead is used for being added to a medium and subjecting T cells to an activation step for more than 36 hours and less than 48 hours.

公开(公告)号：US20190367634A1

公开(公告)日：2019-12-05

申请号：US16546787

申请日：2019-08-21

Applicant: YAMAGUCHI UNIVERSITY ,  NATIONAL CANCER CENTER ,  NOILE-IMMUNE BIOTECH, INC.

Inventor： KOJI TAMADA ,  YUKIMI SAKODA ,  TETSUYA NAKATSURA ,  KEIGO SAITO

IPC: C07K16/30 ,  C07K14/725 ,  C07K14/54 ,  C12N5/078

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

公开(公告)号：US20240400718A1

公开(公告)日：2024-12-05

申请号：US18294359

申请日：2022-08-02

Applicant: Noile-Immune Biotech, Inc.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Keishi ADACHI

IPC: C07K16/42 ,  G01N33/569 ,  G01N33/68

Abstract: The present invention provides an antibody that binds to a linker in a new style of binding. More specifically, the present invention provides an antibody that binds to the linking part between a first region and a linker and the linking part between a linker and a second region in an scFv structure.

公开(公告)号：US20220411739A1

公开(公告)日：2022-12-29

申请号：US17771255

申请日：2020-09-30

Applicant: Noile-Immune Biotech Inc. ,  SHIBUYA CORPORATION

Inventor： Kenji YONEDA ,  Naoya DEGUCHI ,  Noriaki NISHIMURA

IPC: C12M1/42 ,  C12M1/00 ,  C12M1/32

Abstract: A genetically modified cell that can be mass-produced efficiently. The genetically modified cell production system includes a cell-processing isolator for seeding a T cell in a well plate (culture vessel) a cell culture incubator (cell storage) for holding the culture vessel in which the T cell has been seeded and culturing the T cell a virus-processing isolator (nucleic acid preparation isolator) for providing, to the well plate, a virus having a nucleic acid containing a gene to be introduced into a cell a virus storage (nucleic acid storage) for holding the well plate from the virus-processing isolator and a virus infection isolator (nucleic acid introduction isolator) for introducing the nucleic acid into the T cell by infecting the T cell with the virus.

公开(公告)号：US20210309712A1

公开(公告)日：2021-10-07

申请号：US17271451

申请日：2019-08-30

Applicant: NOILE-IMMUNE BIOTECH, INC. ,  Takeda Pharmaceutical Company Limited

Inventor： Chihiro TAKE ,  Takayuki TATAMIYA ,  Akiko YAMAGUCHI

IPC: C07K14/725 ,  C07K14/54 ,  C07K14/715 ,  A61K35/17 ,  A61P35/00

Abstract: The present invention provides immune cells (such as CAR-T cells) having higher antitumor activity than immune cells (such as CAR-T cells) expressing a CAR alone (not expressing cytokines and/or chemokines). A T cell provided in one aspect of the present invention expresses (1) a chimeric antigen receptor (CAR), (2) at least one selected from the group consisting of interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), and interleukin-27 (IL-27), and (3) CC chemokine ligand 19 (CCL19).

公开(公告)号：US20240307451A1

公开(公告)日：2024-09-19

申请号：US18737778

申请日：2024-06-07

Applicant: NOILE-IMMUNE BIOTECH, INC.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Hidenobu ISHIZAKI

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/5418 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

Abstract: The present disclosure provides an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. The present disclosure also provides an isolated immune cell which expresses a receptor, interleukin-7, and chemokine (C-C motif) ligand 19.

公开(公告)号：US20240139248A1

公开(公告)日：2024-05-02

申请号：US18409191

申请日：2024-01-10

Applicant: Noile-Immune Biotech, Inc.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Keishi ADACHI

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C12N15/63

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/521 ,  C07K14/5418 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70575 ,  C12N15/63 ,  A61K38/00

Abstract: An object of the present invention is to provide an immunocompetent cell targeting mesothelin. An immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, interleukin 7 (IL-7), and chemokine (C-C motif) ligand 19 (CCL19) is produced. It is preferred that: the cell surface molecule specifically recognizing human mesothelin should be chimeric antigen receptor (CAR) having single chain antibody, a transmembrane region, and a signaling region that induces the activation of the immunocompetent cell; and the heavy chain variable region and the light chain variable region should be connected via a peptide linker consisting of a 2- to 30-amino acid sequence.

公开(公告)号：US20240018224A1

公开(公告)日：2024-01-18

申请号：US18335477

申请日：2023-06-15

Applicant: Yamaguchi University ,  National Cancer Center ,  Noile-Immune Biotech, Inc.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Tetsuya NAKATSURA ,  Keigo SAITO

IPC: C07K16/18 ,  C12N5/0783 ,  G01N33/68 ,  C07K14/54 ,  C07K14/725 ,  C07K16/30 ,  C12N5/078

CPC classification number: C07K16/18 ,  C12N5/0636 ,  G01N33/68 ,  C07K14/5418 ,  C07K14/7051 ,  C07K16/303 ,  C12N5/0634 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2317/565

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

公开(公告)号：US20200323920A1

公开(公告)日：2020-10-15

申请号：US16956855

申请日：2018-12-19

Applicant: Noile-Immune Biotech, Inc.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Keishi ADACHI

IPC: A61K35/17 ,  C07K14/54 ,  C07K14/52 ,  C07K14/705 ,  C07K14/725 ,  C12N15/63 ,  A61P35/00

Abstract: An object of the present invention is to provide an immunocompetent cell targeting mesothelin. An immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, interleukin 7 (IL-7), and chemokine (C-C motif) ligand 19 (CCL19) is produced. It is preferred that: the cell surface molecule specifically recognizing human mesothelin should be chimeric antigen receptor (CAR) having single chain antibody, a transmembrane region, and a signaling region that induces the activation of the immunocompetent cell; and the heavy chain variable region and the light chain variable region should be connected via a peptide linker consisting of a 2- to 30-amino acid sequence.